Shantanu Kumar BSc, PhD

Shantanu completed his PhD in Microbiology in 2004. During his postdoctoral work at The Scripps Research Institute (TSRI) and University of California San Diego (UCSD), he received training in the area of gene therapy, epigenetics, cancer biology, and stem cell biology. Since past 4 years, his focus has been on genome editing technology (CRISPR/Cas9) and validation of engineered cell lines using advanced technologies.

In addition to R&D work, he also leads first genome editing training course work at EMBL, Heidelberg, Germany. At Juno Therapeutics, he is working with research, analytical and process development (AD&PD) teams to integrate T cells editing at manufacturing scale for early phase clinical trials.